What shaped modern breast oncology and what comes next?

From the pioneering HER2 breakthroughs to the recent innovation of ADCs and oral SERDs, Dr. Rugo provides a masterclass on the therapies that are changing the standard of care. The discussion also looks ahead, exploring the clinical utility of ctDNA monitoring and the critical importance of preserving quality of life in the metastatic setting.

From HER2 breakthroughs and ADC innovation to oral SERDs, ctDNA monitoring, quality of life, and the future of metastatic breast cancer care, this conversation is a masterclass in where the field has been and where it’s heading next.

This is oncology history, innovation, and the future all in one conversation.

🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino

👤 Featuring Dr. Hope Rugo

▶️ Watch on YouTube - https://youtu.be/IGbXzLpE-LY

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #Oncology #OncologyPodcast #HopeRugo #CancerResearch #ClinicalTrials #PrecisionMedicine #MedicalOncology #MedEd #ADC

What does the future of breast oncology look like?

In Episode 4, Dr. Jason Mouabbi and Dr. Paolo Tarantino are joined by Professor Giuseppe Curigliano, Professor of Medical Oncology at the University of Milano, Head of the Experimental Therapeutics Program at the European Institute of Oncology, ESMO President-Elect, and Young Science Talent Scout, to forecast the next decade of breast cancer care.

This conversation looks beyond current standards to the next frontier of breast oncology—from the evolution of ADCs and ctDNA to the emerging roles of bispecifics, radioligand therapy, and cancer vaccines.

We’re mapping out where the science is heading and how it will redefine precision medicine in breast cancer!

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music

#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #PrecisionMedicine #MedEd #MedicalOncology #ESMO #CancerInnovation

It’s March Madness, the Breast Friends Madness way!

In Episode 3, Dr. Jason Mouabbi and Dr. Paolo Tarantino are hitting the court to break down the heavy hitters of 2025 using our "Breast Friends Madness" bracket.

Among the featured lineups are studies ranging from the practice-changing results of the DESTINY-Breast trials to the strategic shifts in SERENA-6, monarchE, and ASCENT-04. We’re scouting the data officially rewriting the playbook for HER2+, TNBC, and HR+ care.

EVERY study in this bracket is a WIN for our patients. Let’s get ready to highlight the trials moving the field forward.

👉 Cast your vote here: tinyurl.com/breastfriendsmadness

▶️ Watch on YouTube

🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox & Amazon Music

#BreastCancer #Oncology #OncologyPodcast #CancerResearch #ClinicalTrials #HER2Positive #TripleNegativeBreastCancer #MedEd #MedicalOncology